Androgen Deprivation Therapy (Relugolix) for the Improvement of Diagnostic Imaging (PSMA PET/CT Scan) in Patients With High Risk or Very High Risk Prostate Cancer, The EnrichPSMA Trial

Abroad (travel likely)RecruitingPHASE2

Conditions

Prostate Adenocarcinoma · Stage IIC Prostate Cancer AJCC v8 · Stage III Prostate Cancer AJCC v8 · Stage IV Prostate Cancer AJCC v8

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Mayo Clinic in Arizona, Scottsdale, Arizona, United States
Contact: Study coordinator (Clinical Trials Referral Office) · mayocliniccancerstudies@mayo.edu · 855-776-0015
Contact: Principal Investigator (Jack R. Andrews, MD)

Study leads

Jack R. Andrews, MD
Principal Investigator
Mayo Clinic

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

A Study of Enzalutamide Plus the Glucocorticoid Receptor Antagonist Relacorilant Versus Placebo for Patients With High-risk Localized Prostate Cancer

Prostate Cancer · Prostate Adenocarcinoma

Abroad (travel likely)RecruitingPHASE2

Chicago, United States · Dallas, United States

PSMA-Directed Para-Aortic Radiation Therapy for Oligorecurrent Prostate Cancer

Prostate Cancer · Prostate Adenocarcinoma · Hormone Sensitive Prostate Cancer

Abroad (travel likely)RecruitingPHASE2

Miami, United States

Neoadjuvant Atezolizumab-Based Combination Therapy in Men With Localized Prostate Cancer Prior to Radical Prostatectomy

Prostate Adenocarcinoma · Prostate Cancer · Localized Prostate Cancer

Abroad (travel likely)RecruitingPHASE2

San Francisco, United States · St Louis, United States

Diagnostic Utility of rhPSMA-7.3 (18F) PET/CT in Men With Prostate Cancer on Active Surveillance

Prostatic Neoplasms · Prostate Cancer · Prostate Adenocarcinoma

Abroad (travel likely)RecruitingPHASE2

New York, United States